EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib are approved precision therapies for advanced non-small cell lung cancer (NSCLC) treatment in patients with drug-sensitizing EGFR-mutant tumors [1–3]. Here, EGFR is linked to non-small cell lung carcinoma.